Masimo (NASDAQ:MASI) Price Target Raised to $250.00

Share on StockTwits

Masimo (NASDAQ:MASI) had its target price hoisted by Raymond James from $235.00 to $250.00 in a research note issued to investors on Wednesday, BenzingaRatingsTable reports. Raymond James currently has an outperform rating on the medical equipment provider’s stock.

A number of other equities research analysts also recently commented on MASI. Stifel Nicolaus lifted their price target on shares of Masimo from $200.00 to $245.00 and gave the stock a buy rating in a report on Wednesday, April 29th. BidaskClub upgraded shares of Masimo from a hold rating to a buy rating in a report on Wednesday, July 8th. UBS Group lifted their price target on shares of Masimo from $207.00 to $245.00 and gave the stock a buy rating in a report on Thursday, April 30th. ValuEngine downgraded shares of Masimo from a buy rating to a hold rating in a report on Friday, May 1st. Finally, BTIG Research reiterated a hold rating on shares of Masimo in a report on Thursday, July 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $216.14.

NASDAQ:MASI opened at $220.12 on Wednesday. The firm has a 50-day moving average price of $228.29 and a two-hundred day moving average price of $202.59. Masimo has a twelve month low of $139.36 and a twelve month high of $258.00. The company has a market capitalization of $12.10 billion, a P/E ratio of 57.03, a price-to-earnings-growth ratio of 4.11 and a beta of 0.92.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, July 28th. The medical equipment provider reported $0.85 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.78 by $0.07. Masimo had a net margin of 21.22% and a return on equity of 16.49%. The firm had revenue of $301.00 million during the quarter, compared to the consensus estimate of $290.09 million. During the same period last year, the firm posted $0.76 EPS. The firm’s revenue for the quarter was up 30.9% on a year-over-year basis. As a group, sell-side analysts predict that Masimo will post 2.74 EPS for the current year.

In other Masimo news, Director Adam Mikkelson sold 1,498 shares of Masimo stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $216.01, for a total transaction of $323,582.98. Following the transaction, the director now directly owns 2,802 shares of the company’s stock, valued at $605,260.02. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Jon Coleman sold 1,250 shares of Masimo stock in a transaction that occurred on Monday, July 6th. The shares were sold at an average price of $235.00, for a total transaction of $293,750.00. Following the transaction, the insider now directly owns 13,715 shares in the company, valued at $3,223,025. The disclosure for this sale can be found here. Insiders sold 3,335 shares of company stock worth $749,625 over the last three months. Corporate insiders own 11.50% of the company’s stock.

Hedge funds have recently made changes to their positions in the business. C M Bidwell & Associates Ltd. acquired a new position in Masimo during the first quarter valued at approximately $25,000. Parallel Advisors LLC lifted its position in shares of Masimo by 272.1% during the second quarter. Parallel Advisors LLC now owns 160 shares of the medical equipment provider’s stock worth $36,000 after purchasing an additional 117 shares in the last quarter. Credit Agricole S A acquired a new position in shares of Masimo during the first quarter worth $29,000. Altshuler Shaham Ltd lifted its position in shares of Masimo by 91.0% during the first quarter. Altshuler Shaham Ltd now owns 170 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 81 shares in the last quarter. Finally, GQ Asset Management LLC acquired a new position in shares of Masimo during the first quarter worth $32,000. 84.39% of the stock is currently owned by hedge funds and other institutional investors.

About Masimo

Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Featured Article: Swap

Analyst Recommendations for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.

 

Latest News

Different Types of Research Papers
Different Types of Research Papers
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing


 
© 2006-2020 BBNS.